Optimi Health Corp. (OPTHF)
| Market Cap | 16.60M |
| Revenue (ttm) | 359.65K |
| Net Income (ttm) | -4.21M |
| Shares Out | n/a |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,655 |
| Average Volume | 13,163 |
| Open | 0.1694 |
| Previous Close | 0.1763 |
| Day's Range | 0.1694 - 0.1780 |
| 52-Week Range | 0.1012 - 0.3830 |
| Beta | 1.15 |
| RSI | 73.66 |
| Earnings Date | Jun 2, 2025 |
About Optimi Health
Optimi Health Corp. produces and supplies psilocybin, psilocin, other psychedelic substances, and functional mushrooms for health and wellness markets in Canada. The company offers raw mushroom biomass, mushroom extracts, and mushroom supplements, as well as a range of manufacturing of drug products. It sells its products through Amazon marketplace and distributors/brokers, as well as online. The company was formerly known as 1251418 BC Ltd. and changed its name to Optimi Health Corp. in August 2020. The company was incorporated in 2020 and is ... [Read more]
Full Company ProfileFinancial Performance
In 2024, Optimi Health's revenue was 389,850, an increase of 115.28% compared to the previous year's 181,087. Losses were -6.04 million, 16.2% more than in 2023.
Financial numbers in CAD Financial StatementsNews
Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
1,000 GMP doses of MDMA now reaching patients with PTSD under Australia's Authorised Prescriber Scheme; Department of Veterans' Affairs to fund treatment for veterans Vancouver, British Columbia--(New...
Optimi Health Obtains U.S. FDA Drug Establishment Registration
The Company is now recognized by the U.S. FDA to support the cross-border supply of GMP MDMA and psilocybin to authorized entities in the United States. Vancouver, British Columbia--(Newsfile Corp. - ...
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufact...
Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
Over 4,000 GMP Capsules Ready to Support PTSD Treatment in Australia, Israel, and Canada Vancouver, British Columbia--(Newsfile Corp. - January 29, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTH...
Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psyched...
Optimi Health Provides Corporate Update
Non-Brokered Private Placement and Debt Settlement Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Compan...
Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
The Company's natural psilocybin extract powers a culturally transformative study to address methamphetamine addiction through indigenous frameworks. Vancouver, British Columbia--(Newsfile Corp. - Jan...
Optimi Health Completes Second MDMA Shipment to Australia and Expands 2025 Production Forecast to Support Over 5,000 Patients Globally
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psyche...
Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin Extract Vancouver, British Columbia--(Newsfile Corp. ...
Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia
Additional 700 Doses Ordered by Mind Medicine Australia as Demand Surges Vancouver, British Columbia--(Newsfile Corp. - October 23, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("...
Optimi Health Announces Leadership Transition
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed manufa...
Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial
Trial to study Major Depressive Disorder using Optimi's GMP natural psilocybin capsules in conjunction with therapy Vancouver, British Columbia--(Newsfile Corp. - August 28, 2024) - Optimi Health Corp...
Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment
Vancouver, British Columbia--(Newsfile Corp. - August 16, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada-licensed psychede...
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
Vancouver, British Columbia and New York, New York--(Newsfile Corp. - August 13, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi"), a GMP-approved, Health Canada licensed ps...
Optimi Health Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-approved, Health Canada licensed psychedel...
Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research
Observational studies to focus on patients with addiction and end-of-life distress pending formal approval and permitting from Thai health authorities Vancouver, British Columbia--(Newsfile Corp. - Ju...
Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant pharmaceu...
Health Canada Issues Three Export Permits to Optimi to Supply Patients Under Australia's Authorised Prescriber Scheme
The Company will ship 160 doses of MDMA and psilocybin to Australian psychiatrists for the treatment of patients with PTSD and Treatment-Resistant Depression. Vancouver, British Columbia--(Newsfile Co...
Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading Health Canada licensed GMP psychedelics...
Optimi Health Awarded Drug Establishment Licence From Health Canada
VANCOUVER, BC , June 3, 2024 /PRNewswire/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a leading Health Canada-licensed psychedelics pharmaceutical manufact...
Optimi Health Announces Closing of Fully Subscribed $1,500,000 Financing
VANCOUVER, BC , May 31, 2024 /PRNewswire/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in con...
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
Optimi Health Provides Corporate Update
VANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a leading Health Canada licensed GMP psychedelics p...
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is...
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.